<< Back
View printer-friendly version
Aptevo Therapeutics Presents New Patient-Reported Data With IXINITY

Data Presented at the Thrombosis and Hemostasis 2018 Summit of North America

SEATTLE, March 12, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that new patient-reported outcomes data for IXINITY® [Coagulation Factor IX (Recombinant)] were presented at the Thrombosis and Hemostasis 2018 Summit of North America, supporting a positive benefit for IXINITY in patients with Hemophilia B.

The data presented were from a patient-reported outcomes study of patients with Hemophilia B currently being treated with IXINITY.  The study was designed to generate a descriptive analysis of patient experiences on IXINITY and used a questionnaire to capture patient-reported responses to various clinical and quality of life questions.  This study has several limitations that should be considered when evaluating the results including a small sample size, a potential for selection bias and recall bias among participants, and the use of non-validated outcomes measures.

Overall, patients reported a high level of satisfaction with IXINITY with low annualized bleed rates and low impact on quality of life scores.  In the study:

  • 89% of patients reported that they were very satisfied or somewhat satisfied with IXINITY
  • Since starting IXINITY, a majority of patients reported that they were very active (22%) or somewhat active (56%)
  • The median reported annualized bleed rate (ABR) among patients taking IXINITY for prophylaxis was 1.6, which is consistent with the median ABR seen in the pivotal clinical trial, which was 1.52
  • A majority of patients on IXINITY reported no problems or slight problems on all domains of quality of life: mobility, self-care, usual daily activities, pain or discomfort, anxiety or depression.

“Anecdotal reports from patients who have switched their factor IX therapy to IXINITY appear to suggest some clinical and quality of life benefit associated with IXINITY therapy,” said Dr. Scott Stromatt, Chief Medical Officer for Aptevo.  “We undertook the current outcomes study to try and gain a better understanding of how IXINITY was being used in the real world setting and to attempt to validate some of these anecdotal observations. While the results must be interpreted with caution, as there are many limitations to this type of study, such as its small size and retrospective nature, we were intrigued to see trends supportive of a positive patient benefit with IXINITY.  As patients are known to respond to factor IX options differently, we see value in having a variety of options available for patients and look forward to building on the data set for IXINITY,” said Dr. Stromatt.

Launched in the United States in 2015 and wholly-owned by Aptevo, IXINITY is an intravenous recombinant factor IX therapeutic for use in people 12 years of age or older with Hemophilia B – a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding.

About Hemophilia B

Hemophilia B is a congenital bleeding disorder caused by a deficiency of coagulation factor IX. It affects approximately 1:25,000 male births, with approximately 4,000 persons affected in the U.S. The clinical spectrum may include spontaneous or trauma-induced bleeding into joints, muscles, and soft tissues, resulting in joint damage, reduction in mobility, and severe arthritis, all of which negatively impact health-related quality of life. The primary aim of care is to prevent and treat bleeding by replacing the deficient clotting factor.


IXINITY is indicated for the control and prevention of bleeding episodes and for perioperative management for adults and children ≥12 years of age with Hemophilia B. IXINITY is not indicated for induction of immune tolerance in patients with Hemophilia B. IXINITY contains recombinant coagulation factor IX (trenonacog alfa). Trenonacog alfa is a purified single chain glycoprotein derived from Chinese hamster ovary (CHO) cells and has an amino acid sequence that is comparable to the Thr148 allelic form of plasma-derived factor IX. No human or animal proteins are added during any stage of manufacturing or formulation of IXINITY. The recombinant factor IX is purified by a chromatography purification process. The process includes three validated steps for virus inactivation and removal. The process also includes a validated manufacturing step to reduce the presence of CHO proteins in the final drug product.

Indications and Important Risk Information

IXINITY [Coagulation Factor IX (Recombinant)] Lyophilized Powder for Solution for Intravenous Injection is a coagulation factor IX (recombinant) indicated in adults and children ≥ 12 years of age with Hemophilia B for control and prevention of bleeding episodes, and for perioperative management. IXINITY is not indicated for induction of immune tolerance in patients with Hemophilia B. IXINITY is contraindicated in patients who have known hypersensitivity to IXINITY or its excipients, including hamster protein.

Hypersensitivity reactions, including anaphylaxis, may occur following IXINITY administration. Discontinue use of IXINITY if hypersensitivity symptoms occur, and initiate appropriate treatment. Regularly evaluate patients for the development of factor IX inhibitors by appropriate clinical observations and laboratory tests. If expected factor IX activity plasma levels are not attained, or, if bleeding is not controlled as expected with a certain dose, perform an assay that measures factor IX inhibitor concentration. An association between the occurrence of a factor IX inhibitor and allergic reactions has been reported. Individuals with factor IX inhibitors may be at increased risk of severe hypersensitivity reactions or anaphylaxis if re-challenged.

Nephrotic syndrome may occur with IXINITY. Nephrotic syndrome has been reported following attempted immune tolerance induction in Hemophilia B patients with factor IX inhibitors and a history of allergic reactions. Thromboembolism may occur when using IXINITY (e.g., pulmonary embolism, venous thrombosis, and arterial thrombosis). Patients may develop hypersensitivity to hamster (CHO) protein as IXINITY contains trace amounts. The most common adverse drug reaction observed in >2% of patients in clinical trials was headache.

Please see full Prescribing Information at www.IXINITY.com.

About Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. is a biotechnology company focused on novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Our core technology is the ADAPTIR™ (modular protein technology) platform. Aptevo has four commercial products in the areas of hematology and infectious diseases, as well as various investigational stage product candidates in immuno-oncology.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including, without limitation, statements regarding IXINITY, our technology and related pipeline, the potential for regulatory approvals, collaboration and partnership opportunities, commercial portfolio, Aptevo’s future growth rates, Aptevo’s ability to timely manufacture its products, and any other statements containing the words “believes,” “expects,” “anticipates,” “intends,” “plans,” “forecasts,” “estimates,” “will” and similar expressions are forward-looking statements. These forward-looking statements are based on Aptevo’s current intentions, beliefs and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo’s expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not undertake to update any forward-looking statement to reflect new information, events or circumstances.

There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements, including possible negative effects on our business operations, assets or financial results as a result of the separation; a deterioration in our business or prospects; the ability to obtain regulatory approvals; the ability of our contractors and suppliers to supply product and materials;  our ability and the ability of our contractors and suppliers to maintain compliance with cGCP and other regulatory obligations; the results of regulatory inspections; adverse developments in our customer-base or markets and our ability to retain patients; adverse developments in the U.S. or global capital markets, credit markets or economies generally; and changes in regulatory, social and political conditions. Additional risks and factors that may affect results are set forth in our filings with the Securities and Exchange Commission, including Aptevo’s most recent Annual Report on Form 10-K, as filed on March 31, 2017. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement.


Aptevo Therapeutics
Stacey Jurchison
Senior Director, Investor Relations and Corporate Communications

Primary Logo

Source: Aptevo Therapeutics Inc.